Immune cell study in liver cancer patients on immunotherapy
Part of Cancer, Immune system & allergy clinical trials.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be removed with surgery.
- You are about to start one of these two treatments as your first therapy: atezolizumab plus bevacizumab or tremelimumab plus durvalumab.
- You are between 18 and 89 years old.
- You do not have an active autoimmune disease or chronic inflammatory condition.
- You do not have a life expectancy of less than 12 months due to other illnesses.
- You have no history of other cancers in the last 3 years, except for certain low-risk or completely treated cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This study looks at how well immunotherapy combinations work as the first treatment for advanced liver cancer that can't be surgically removed. It will track real-world patients to see how safe and effective these treatments are.
This trial is testing how well immune checkpoint inhibitors, which help the body's immune system fight cancer, work in people with advanced liver cancer. The goal is to see if these drugs are effective and safe for patients whose liver is still working reasonably well.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Hear when a new Advanced HCC Treated by Systemic Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.